Literature DB >> 6331549

Characterization of a novel HTLV-infected cell line.

H P Koeffler, I S Chen, D W Golde.   

Abstract

A man from Chile developed an aggressive mature T cell leukemia associated with marked eosinophilia. The neoplastic lymphocytes were of T helper surface phenotype, and they expressed the p24 and p19 antigens of human T cell leukemia virus (HTLV). A cell line (ME) was established from the patient's peripheral blood cells that was initially composed of eosinophils and T and B lymphocytes. The B lymphocytes of the cell line are polyclonal and contain Epstein-Barr virus (EBV) DNA. Many of the T lymphocytes, a few of the B lymphocytes, and none of the eosinophils express HTLV p19 and p24 antigens. By 6 months of culture, the ME line no longer contained eosinophils. A variant line of ME was established; this variant (ME-2) is notable because the cells (greater than 80%) adhere tightly to the bottom of the culture flask; they do not express T lymphocyte markers, but 30% of the cells contain cytoplasmic mu heavy immunoglobulin chains. These pre-B and null lymphocytes contain p19 and p24 antigens (80% of cells), have the HTLV-I genome, and are able to transform normal T lymphocytes in vitro. We isolated a B lymphocyte clone (11A) from ME that expresses cytoplasmic immunoglobulin (70% of cells) and p19 and p24 antigens (75% of cells), contains the EBV and HTLV genomes, and can transform T lymphocytes from normal volunteers. These data show that B lymphocytes can be infected with HTLV, although no disease of HTLV-infected B lymphocytes has been reported. The T lymphocytes from normal adult peripheral blood were easily immortalized (about 70% efficiency) by cocultivation with lethally irradiated ME cells. Twenty-five of 27 of the transformant lines were composed of T lymphocytes with helper antigens, and two of the lines were of T suppressor antigen phenotype. All the cell lines that were tested constitutively produce lymphokines, including colony-stimulating factor (CSF), erythroid-potentiating activity (EPA), macrophage migration-inhibitory factory (MIF), neutrophil-inhibitory factor (NIF), and differentiation-inducing factor (DIF).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331549

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.

Authors:  L D Papsidero; R P Dittmer; L Vaickus; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

2.  Assessment of DNA 'fingerprinting' as a method for validating the identity of cancer cell lines maintained in long-term culture.

Authors:  M F Fey; A Tobler
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

3.  Human T cell leukemia virus type I tax-induced IκB-ζ modulates tax-dependent and tax-independent gene expression in T cells.

Authors:  Ryuichiro Kimura; Masachika Senba; Samuel J Cutler; Stephen J Ralph; Gutian Xiao; Naoki Mori
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

4.  Constitutive expression of the HTLV-I pX and env regions in Jurkat T-cells induces differential activation of SRE, CRE and NF kappa B pathways.

Authors:  A C Black; J Luo; S Chun; S Tabibzadeh
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

5.  Immunodetection of human T-cell lymphotropic virus type I core protein in biological samples by using a monoclonal antibody immunoassay.

Authors:  L Papsidero; F Swartzwelder; M Sheu; R Montagna; G Ehrlich; S Bhagavati; H Dosik; J Sninsky; B Poiesz
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

6.  Serological evaluation of Escherichia coli-expressed human T-cell leukemia virus type I env, gag p24, and tax proteins.

Authors:  S R Coates; A J Harris; D L Parkes; C M Smith; H L Liu; R W Akita; M M Ferrer; E K Sampson; J W Brandis; M X Sliwkowski
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

7.  Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1-infected cells.

Authors:  Emi Ikebe; Sahoko Matsuoka; Kenta Tezuka; Madoka Kuramitsu; Kazu Okuma; Makoto Nakashima; Seiichiro Kobayashi; Junya Makiyama; Makoto Yamagishi; Seiichi Oyadomari; Kaoru Uchimaru; Isao Hamaguchi
Journal:  Blood Adv       Date:  2020-05-12

8.  Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells.

Authors:  Mariko Tomita; Gregg L Semenza; Canine Michiels; Takehiro Matsuda; Jun-Nosuke Uchihara; Taeko Okudaira; Yuetsu Tanaka; Naoya Taira; Kazuiku Ohshiro; Naoki Mori
Journal:  Biochem J       Date:  2007-09-01       Impact factor: 3.857

9.  Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.

Authors:  Naoki Mori; Takehiro Matsuda; Masayuki Tadano; Takao Kinjo; Yasuaki Yamada; Kunihiro Tsukasaki; Shuichi Ikeda; Yoshihiro Yamasaki; Yuetsu Tanaka; Takao Ohta; Teruo Iwamasa; Masao Tomonaga; Naoki Yamamoto
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages.

Authors:  B Chesebro; J Nishio; S Perryman; A Cann; W O'Brien; I S Chen; K Wehrly
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.